eMediNews
(Incorporating eIMA News)
19th February 2016
Editorial
New anti-TB drugs 
 
As per Dr Soumya Swaminathan, DG ICMR, "The phase-3 clinical trials (on humans) of drug Bedaquilin has been successfully carried out in Africa, and the drug is likely to come to India next month." Another drug called Linezolid, which is in the final stages of human trials. 

"The WHO attempts to make the world TB-free by 2035, while for India, it is 2050."

Bedaquiline 
  • Bedaquiline (Sirturo), the diarylquinoline TMC207, is a bactericidal antituberculous agent with a novel mechanism of mycobacterial adenosine triphosphate (ATP) synthase inhibition. 
  • Among 440 patients with MDR-TB in two phase II clinical trials, those who received bedaquiline in combination with optimized background regimens had faster and more frequent conversion to negative sputum culture than patients receiving the background regimens only (77.6 vs 57.6 percent) (N Engl J Med 2009;360:2397).
  • Bedaquiline received accelerated approval by the US Food and Drug Administration (FDA) in December 2012 for use as part of combination therapy to treat adults with multidrug-resistant (MDR) pulmonary TB when other alternatives are not available. Dosing consists of 400 mg orally once daily for two weeks, followed by 200 mg orally three times weekly for a total treatment duration of 24 weeks. 
  • Bedaquiline is given with food and in combination with other TB drugs. Drug-drug interactions have been observed with CYP3A4 inducers (e.g., rifampin reduced bedaquiline exposure by approximately 50 percent) and CYP3A4 inhibitors (e.g., ketoconazole increased bedaquiline exposure by approximately 22 percent) 
  • The FDA approved bedaquiline with a boxed warning alerting that it can cause QT prolongation, which could lead to cardiac arrhythmia or death. 
  • In October 2013, provisional guidelines were issued by the United States Centers for Disease Control and Prevention (CDC) for use of bedaquiline that recommend clinical expert consultation and directly observed therapy (DOT) as part of a comprehensive case management strategy for cases where the drug is used. 
  • In children, pregnant women, individuals with extrapulmonary MDR-TB, and individuals with HIV or other comorbid conditions, CDC indicates that, although safety and effectiveness in these populations have not been determined, bedaquiline may be used on a case-by-case basis in these individuals when an effective treatment regimen cannot otherwise be provided. 
Linezolid has modest bactericidal activity against TB. Its use is limited by adverse events (bone marrow suppression, neuropathy) and cost.
To Read More or Comment, Click Here
Top News
Practice Updates
69th IDC 2016
Video of the Day
Webcast
Top posts of the week on eMediNexus
Lifestyle Updates
Lighter Reading
Medicolegal Corner
eMedi Quiz
Photo Quiz
 
 
 
Quizzes and Cases
ANSWER OUR QUIZZES AND GET FEATURED ON EMEDINEWS
Press Release
Rule 3(3)(1)(b) of the PNDT Rules is ultra vires and non-pelvic ultrasonologists to be exempted from the PCPNDT act with some riders
 
New Delhi, February 18, 2016: In a landmark judgment W.P. (C) 2721/2014: Indian Medical Association vs. Union OF India, IMA has been successful in fighting for the rights of the medical fraternity. As per the latest High Court judgment released yesterday, registered medical practitioners, MBBS graduates, are no longer required to undertake additional six month training and pass an examination in order to perform ultrasounds. In addition to this, the rules of the PCPNDT will no longer be applicable to non-pelvic ultrasonologists subject to a few riders.

Commenting on this achievement, Dr S S Agarwal, National President and Padma Shri Awardee Dr K K Aggarwal, Honorary Secretary General IMA in a joint statement said,” The rights of the medical fraternity and overall healthcare benefit of the society are our top priorities. We have been fighting this case with full force and determination over the past two years and are extremely happy that the judgment has been passed in our favor. The laws were unjust to the medical fraternity and were increasing the violence against doctors as well as causing an unwarranted fear amongst them. We look forward to the implementation of this judgment.”
To Read More or Comment, Click Here
IMA Updates
 
 
IMA Polio Dates
  • April 1st: tOPV would not be available after this date.
  • April 11th: bOPV would be available in private market but it is not to be opened or used before 25th April.
  • April 25: IMA Polio Switch Day, when tOPV would be completely withdrawn and replaced by bOPV in both routine immunization and polio campaigns.
  • 9th May: IMA National Validation Day when India would be declared free of tOPV. 

IMA Satyagraha - https://www.youtube.com/watch?v=UV1zCH33BlU

Dr Good Dr Bad                                                          Make Sure
eIMA News Update
Digital IMA
The Indian Medical Association (IMA) presents a series of weekly webcasts for the benefit of the Indian medical profession, engaging you with the latest in advocacy efforts for doctors, through an interactive exclusive digital webcast partnership with eMediNexus.

Next Webcast: 25
th February 2016